ATE190494T1 - Verwendung von gnrh-antagonisten zur herstellung eines medikaments zur behandlung gonaden-steroid abhängiger erkrankungen - Google Patents

Verwendung von gnrh-antagonisten zur herstellung eines medikaments zur behandlung gonaden-steroid abhängiger erkrankungen

Info

Publication number
ATE190494T1
ATE190494T1 AT95927228T AT95927228T ATE190494T1 AT E190494 T1 ATE190494 T1 AT E190494T1 AT 95927228 T AT95927228 T AT 95927228T AT 95927228 T AT95927228 T AT 95927228T AT E190494 T1 ATE190494 T1 AT E190494T1
Authority
AT
Austria
Prior art keywords
medication
treating
producing
dependent diseases
gnrh antagonists
Prior art date
Application number
AT95927228T
Other languages
English (en)
Inventor
Gary D Hodgen
Audrey Philips
Original Assignee
Hampton Roads Medical College
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE190494(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,860 external-priority patent/US5658884A/en
Application filed by Hampton Roads Medical College, Ortho Pharma Corp filed Critical Hampton Roads Medical College
Application granted granted Critical
Publication of ATE190494T1 publication Critical patent/ATE190494T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95927228T 1994-07-22 1995-07-18 Verwendung von gnrh-antagonisten zur herstellung eines medikaments zur behandlung gonaden-steroid abhängiger erkrankungen ATE190494T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27959394A 1994-07-22 1994-07-22
US08/467,860 US5658884A (en) 1994-07-22 1995-06-06 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
PCT/US1995/008996 WO1996003138A1 (en) 1994-07-22 1995-07-18 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Publications (1)

Publication Number Publication Date
ATE190494T1 true ATE190494T1 (de) 2000-04-15

Family

ID=26959766

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95927228T ATE190494T1 (de) 1994-07-22 1995-07-18 Verwendung von gnrh-antagonisten zur herstellung eines medikaments zur behandlung gonaden-steroid abhängiger erkrankungen

Country Status (29)

Country Link
EP (1) EP0769956B1 (de)
JP (1) JP3138477B2 (de)
CN (1) CN1137722C (de)
AP (1) AP775A (de)
AT (1) ATE190494T1 (de)
AU (1) AU691952B2 (de)
BG (1) BG63363B1 (de)
BR (1) BR9508718A (de)
CA (1) CA2195745C (de)
CY (1) CY2228B1 (de)
CZ (1) CZ291803B6 (de)
DE (1) DE69515666T2 (de)
DK (1) DK0769956T3 (de)
EE (1) EE03515B1 (de)
ES (1) ES2145286T3 (de)
FI (1) FI970244A0 (de)
GR (1) GR3033590T3 (de)
HU (1) HU218910B (de)
IL (1) IL114655A (de)
IS (1) IS4413A (de)
LV (1) LV11823B (de)
MX (1) MX9700574A (de)
NO (1) NO970257L (de)
NZ (1) NZ290554A (de)
OA (1) OA10730A (de)
PT (1) PT769956E (de)
RU (1) RU2181598C2 (de)
SK (1) SK282118B6 (de)
WO (1) WO1996003138A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
CA2383510A1 (en) * 1999-09-23 2001-03-29 Zentaris Ag Method for the therapeutic management of extrauterine proliferation of endometreial tissue, chronic pelvic pain and fallopian tube obstruction
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2095818A1 (de) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Verwendung von LHRH-Antagonisten in nicht-kastrierenden Dosen
WO2009145690A1 (en) * 2008-05-29 2009-12-03 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
CN114306347A (zh) * 2015-05-18 2022-04-12 康堤医疗有限公司 用于治疗性激素依赖性疾病的双重nk-1/nk-3受体拮抗剂
EP3560555A1 (de) 2018-04-26 2019-10-30 LifeArc Zusammensetzung zur behandlung einer oder mehrerer östrogenvermittelter krankheiten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
BG63363B1 (bg) 2001-11-30
AU691952B2 (en) 1998-05-28
FI970244A (fi) 1997-01-21
DE69515666D1 (de) 2000-04-20
JP3138477B2 (ja) 2001-02-26
NZ290554A (en) 2000-08-25
BG101158A (en) 1997-09-30
HU218910B (hu) 2000-12-28
LV11823B (en) 1998-03-20
LV11823A (lv) 1997-08-20
EP0769956B1 (de) 2000-03-15
SK282118B6 (sk) 2001-11-06
AP9700913A0 (en) 1997-01-31
EE03515B1 (et) 2001-10-15
CN1137722C (zh) 2004-02-11
IS4413A (is) 1997-01-14
CZ291803B6 (cs) 2003-06-18
HU9700046D0 (en) 1997-02-28
CZ15097A3 (en) 1997-11-12
ES2145286T3 (es) 2000-07-01
FI970244A0 (fi) 1997-01-21
IL114655A (en) 2005-08-31
IL114655A0 (en) 1995-11-27
CA2195745C (en) 2005-03-29
NO970257D0 (no) 1997-01-21
EP0769956A1 (de) 1997-05-02
AU3132095A (en) 1996-02-22
DK0769956T3 (da) 2000-06-05
NO970257L (no) 1997-01-21
CA2195745A1 (en) 1996-02-08
CY2228B1 (en) 2003-04-18
EE9700208A (et) 1998-02-16
SK7097A3 (en) 1997-11-05
DE69515666T2 (de) 2000-07-06
OA10730A (en) 2001-06-07
BR9508718A (pt) 1997-12-30
HUT77127A (hu) 1998-03-02
EP0769956A4 (de) 1999-03-10
GR3033590T3 (en) 2000-09-29
AP775A (en) 1999-10-28
WO1996003138A1 (en) 1996-02-08
CN1200674A (zh) 1998-12-02
JPH10503203A (ja) 1998-03-24
RU2181598C2 (ru) 2002-04-27
MX9700574A (es) 1997-12-31
PT769956E (pt) 2000-07-31

Similar Documents

Publication Publication Date Title
ATE195527T1 (de) Neue steroidester zur behandlung von hauterkrankungen
ATE331522T1 (de) Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
DE69307509D1 (de) Vorrichtung zur behandlung von herzfehlern
DE69124293D1 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
DE69331207D1 (de) Verfahren zur Behandlung eines resorbierbaren Implantationsmaterials
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE69509544D1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE69405406D1 (de) Verfahren zur herstellung von einer medizinischen stimulationselektrode
DE69507419D1 (de) Verwendung von einem Tetrahydropyridin- oder azabicyclischen Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen
DE60015392D1 (de) Verwendung von annexin-modulatoren zur herstellung eines medikaments zur behandlung und/oder vorbeugung von arthritis und arthritischen erkrankungen
DE3585607D1 (de) Verwendung von paroxetine zur herstellung eines arzneimittel zur behandlung von obesitaet.
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69619753D1 (de) Verwendung mindestens eines die Tripeptidsequenz Lys-DPro-Arg enthaltenden Peptids zur Herstellung eines Arzneimittels zur Behandlung einer Entzündung
DE69637449D1 (de) Verwendung von alpha-hydroxysäuren zur herstellung eines arzneimittels für die behandlung von entzündungen
ATE190494T1 (de) Verwendung von gnrh-antagonisten zur herstellung eines medikaments zur behandlung gonaden-steroid abhängiger erkrankungen
DE69512760D1 (de) Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
DE69635298D1 (de) Verwendung von Acetylsalicylsäuren zur Herstellung eines Medikaments für die Behandlung von Hautverletzungen
DE69318909D1 (de) Verfahren zur Herstellung von menschlichem Wachstumshormon
DE69621447D1 (de) Verwendung von nitroflavonoide zur behandlung von angstzuständen
DE69613168D1 (de) Verwendung eines CGRP Antagonisten zur Behandlung von Flechten und Pruritus und so erhaltene Zubereitung
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE59010245D1 (de) Strahlungsempfindliches Gemisch und Verfahren zur Herstellung von Reliefstrukturen
DE69209140D1 (de) Verwendung Glycine/NMDA-Rezeptorliganden zur Herstellung eines Arzneimittels zur Behandlung von Drogenabhängigkeit und Entzugserscheinungen
DE69607559D1 (de) Verfahren zur Behandlung von Phenolteer

Legal Events

Date Code Title Description
EEFA Change of the company name
RZN Patent revoked